MacroGenics Q3 2021 Earnings Report
Key Takeaways
MacroGenics reported Q3 2021 financial results, with total revenue of $15.7 million, including $3.6 million in MARGENZA net sales. The company's cash, cash equivalents, and marketable securities were $298.9 million as of September 30, 2021. An IND application was submitted for MGD024, and the FDA approved MacroGenics’ GMP manufacturing facility to produce MARGENZA® drug substance.
Submitted Investigational New Drug (IND) application for MGD024, a next-generation DART® molecule targeting CD123 and CD3 for AML.
Received U.S. FDA approval for MacroGenics’ GMP manufacturing facility to produce MARGENZA® drug substance.
Discontinued enrollment of Cohort A of Phase 2/3 MAHOGANY study of margetuximab.
Zai Lab’s Bridging Study of margetuximab plus chemotherapy in advanced, previously treated HER2-positive breast cancer met its primary endpoint.
MacroGenics
MacroGenics
Forward Guidance
MacroGenics anticipates that its cash, cash equivalents and marketable securities as of September 30, 2021, plus anticipated and potential collaboration payments, should enable it to fund its operations through 2023, assuming the Company’s programs and collaborations advance as currently contemplated.